Skip to content. Skip to navigation
Personal tools
  Members Area  

ANZCA

Sections
You are here: Home Events ANZCA Annual Scientific Meetings 2008 ASM Abstracts Disc arthroplasty - surgical update
Navigation
News
02-09-2008
September 2008 Trial Resource
Online trial
28-08-2008
August 2008
24-08-2008
New drug
A new drug has just been approved for use in Australia. SITAGLIPTIN (Januvia) is an oral drug for type 2 Diabetes mellitus. It is a new class of drug, a dipeptidyl peptidase (DPP-4) inhibitor. Sitagliptin is an 'incretin enhancer' that increases the levels of active incretin by inhibiting their metabolism by DPP-4, thus prolonging their effect in stimulating insulin release and decreasing glucagon secretion.
24-08-2008
Latest ANZCA e-newsletter online
The latest edition of ANZCA’s e-newsletter has now been emailed to Fellows, trainees and ANZCA staff.
21-08-2008
Fellowship Affairs
The first meeting of the Fellowship Affairs Committee was held on Friday, 15 August 2008. Chaired by Dr Margaret Cowling, the Committee oversees all matters directly pertinent to Fellows, including CPD, annual scientific meetings, Regional CME and SIG events, communications and professional issues
More news…
 
Document Actions

Disc arthroplasty - surgical update

Nicholas Little

Royal North Shore Hospital, Sydney, Australia

cSpinal disc arthroplasty is a rapidly expanding and controversial area of spinal surgery. Whether it is evolution, revolution or just another substantial source of income for prosthesis companies remains to be seen. I will discuss briefly the history of surgery to fuse the spine and the rationale behind arthroplasty. I will present the surgical and anaesthetic challenges presented by arthroplasty and the results that are available for this treatment to date.
The differences in constraint and mobility of prostheses will be considered along with the clinical consequences.
Orthopods have known for a long time that to fuse a painful joint will often make it less painful. This approach had a substantial mechanical cost to the patient and has lead to arthroplasty becoming the gold standard for treatment of large painful/degenerative peripheral joints (eg. Hips, knees). Whether this mechanical benefit of arthroplasty over fusion applies to the spine is the crux of the discussion. The mechanical consequences of spinal fusion at one level are significantly less than that of a large peripheral joint. The indications for spinal surgery, often for axial pain, are often far less clear than that for other joints and outcome measures are flawed. In the end is the argument against arthroplasty one of cost control (as has recently occurred with cervical arthroplasty in Australia) or are there other dangers of embracing this technology. There are specific risks with both cervical and lumbar arthroplasty and will seductive new technology lead to expansion of indications beyond what is reasonable.
As with most areas of medicine we need to critically evaluate new technology and procedures with an eye on individual patient benefit in the context of ever increasing financial burden on the system. Conflicts and barriers to good medical care such as relationships between prosthesis companies and surgeons need to be transparent or avoided where possible.
I believe spinal arthroplasty will grow in popularity and is an appropriate treatment strategy, which will change the way we think about spinal mechanics. How we handle this revolution is a challenge requiring care and restraint.